Similar articles

Abstract: Objective: The ideal medication for the treatment of acid-related diseases, e.g., peptic ulcers, stress-related gastric bleeding, functional dyspepsia, and gastroesophageal reflux disease, should have a rapid onset of action to promote hemostasis and relieve the symptoms. The aim of our study was to investigate the inhibitory effects on gastric acid secretion of a single oral administration of a proton pump inhibitor, omeprazole 20 mg, and an h₂-receptor antagonist, roxatidine 75 mg. Methods: Ten Helicobacter pylori-negative male subjects participated in this randomized, two-way crossover study. intragastric pH was monitored continuously for 6 h after single oral administration of omeprazole 20 mg and roxatidine 75 mg. Each administration was separated by a 7-d washout period. Results: During the 6-h study period, the average pH after administration of roxatidine was higher than that after administration of omeprazole (median: 4.45 vs. 2.65; P=0.0367). Also during the 6-h study period, a longer duration of maintenance at pH above 2, 5, and 6 was observed after administration of roxatidine 75 mg than after administration of omeprazole 20 mg (median: 90.6% vs. 55.2%, P=0.0284; 43.7% vs. 10.6%, P=0.0125; 40.3% vs. 3.3%, P=0.0125; respectively). Conclusions: In Helicobacter pylori-negative healthy male subjects, oral administration of roxatidine 75 mg increased the intragastric pH more rapidly than that of omeprazole 20 mg.

[1]Abe, Y., Inamori, M., Togawa, J., Kikuchi, T., Muramatsu, K., Chiguchi, G., Kawamura, H., Kobayashi, N., Kirikoshi, H., Sakaguchi, T., et al., 2004. The comparative effects of single intravenous doses of omeprazole and famotidine on intragastric pH. J. Gastroenterol., 39(1):21-25.

[2]Andersson, T., 1996. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin. Pharmacokinet., 31(1):9-28.

[3]Arnestad, J.S., Kleveland, P.M., Waldum, H.L., 1997. In single doses ranitidine effervescent is more effective than lansoprazole in decreasing gastric acidity. Aliment. Pharmacol. Ther., 11(2):355-358.

[4]Burget, D.W., Chiverton, S.G., Hunt, R.H., 1990. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relation-ship between ulcer healing and acid suppression. Gastroenterology, 99(2):345-351.

[5]Chassany, O., Bergmann, J.F., Simoneau, G., Elouaer-Blanc, L., Segrestaa, J.M., Caulin, C., 1996. The comparative effects of single intravenous doses of cimetidine, ranitidine, famotidine, and omeprazole on intragastric pH. Curr. Ther. Res., 57(3):159-169.

[6]Green, F.W.Jr., Kaplan, M.M., Curtis, L.E., Levine, P.H., 1978. Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor pro-longed gastroduodenal mucosal hemorrhage. Gastroenterology, 74(1):38-43.

[7]de Morais, S.M., Wilkinson, G.R., Blaisdell, J., Meyer, U.A., Nakamura, K., Goldstein, J.A., 1994a. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol., 46(4):594-598.

[8]de Morais, S.M., Wilkinson, G.R., Blaisdell, J., Nakamura, K., Meyer, U.A., Goldstein, J.A., 1994b. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem., 269(22):15419-15422.

[9]Ducrotté, P., Guillemot, F., Elouaer-Blanc, L., Hirschauer, C., Thorel, J.M., Petit, A., Hochain, P., Michel, P., Cortot, A., Colin, R., et al., 1994. Comparison of omeprazole and famotidine on esophageal pH in patients with moderate to severe esophagitis: a cross-over study. Am. J. Gastroenterol., 89(5):717-721.

[10]Frank, W.O., Peace, K.E., Watson, M., Seaman, J.J., Szego, P.L., Braverman, A., Mico, B., Dickson, B., 1986. The effect of single intravenous doses of cimetidine or ranitidine on gastric secretion. Clin. Pharmacol. Ther., 40(6):665-672.

[11]Fullarton, G.M., Macdonald, A.M., Mann, S.G., McColl, K.E., 1991. Controlled study of the effects of intravenous famotidine on intragastric pH in bleeding peptic ulcers. Aliment. Pharmacol. Ther., 5(1):77-84.

[12]Furuta, T., Ohashi, K., Kosuge, K., Zhao, X.J., Takashima, M., Kimura, M., Nishimoto, M., Hanai, H., Kaneko, E., Ishizaki, T., 1999. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin. Pharmacol. Ther., 65(5):552-561.

[13]Hedenstrom, H., Alm, C., Kraft, M., Grahnen, A., 1997. Intragastric pH after oral administration of single doses of ranitidine effervescent tablets, omeprazole capsules and famotidine fast-dissolving tablets to fasting healthy volunteers. Aliment. Pharmacol. Ther., 11(6):1137-1141.

[14]Howden, C.W., Forrest, J.A., Reid, J.L., 1984. Effects of single and repeated doses of omeprazole on gastric acid and pepsin secretion in man. Gut, 25(7):707-710.

[15]Hurlimann, S., Abbuhl, B., Inauen, W., Halter, F., 1994. Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole. Aliment. Pharmacol. Ther., 8(2):193-201.

[16]Ichikawa, T., Ishihara, K., Kusakabe, T., Kawakami, T., Hotta, K., 1999. Stimulant effects of nitric oxide generator and roxatidine on mucin biosynthesis of rat gastric oxyntic mucosa. Life Sci., 65(4):PL41-PL46.

[17]Iida, H., Inamori, M., Akimoto, K., Mawatari, H., Endo, H., Nozaki, Y., Akiyama, T., Ikeda, T., Sakamoto, Y., Fujita, K., et al., 2009. Early effects of intravenous administrations of lansoprazole and famotidine on intragastric pH. Hepatogastroenterology, 56(90):551-554.

[18]Inamori, M., Togawa, J., Iwasaki, T., Ozawa, Y., Kikuchi, T., Muramatsu, K., Chiguchi, G., Matsumoto, S., Kawamura, H., Abe, Y., et al., 2005. Early effects of lafutidine or rabeprazole on intragastric acidity: which drug is more suitable for on-demand use? J. Gastroenterol., 40(5):453-458.

[19]Ishizaki, T., Horai, Y., 1999. Cytochrome P450 and the metabolism of proton pump inhibitors: emphasis on rabeprazole. Aliment. Pharmacol. Ther., 13(s3):27-36.

[20]Jansen, J.B., Lundborg, P., Baak, L.C., Greve, J., Ohman, M., Stöver, C., Röhss, K., Lamers, C.B., 1988. Effect of single and repeated intravenous doses of omeprazole on pentagastrin stimulated gastric acid secretion and pharmacokinetics in man. Gut, 29(1):75-80.

[21]Khoury, R.M., Katz, P.O., Castell, D.O., 1999. Post-prandial ranitidine is superior to post-prandial omeprazole in control of gastric acidity in healthy volunteers. Aliment. Pharmacol. Ther., 13(9):1211-1214.

[22]Kubota, T., Chiba, K., Ishizaki, T., 1996. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin. Pharmacol. Ther., 60(6):661-666.

[23]Moore, J.G., 1991. Stress ulceration in the intensive care unit: use of H₂-receptor antagonists. Aliment. Pharmacol. Ther., 5(s1):111-119.

[24]Nakamura, M., Oda, M., Akiba, Y., 1995. Autoradiographic demonstration of lansoprazole uptake sites in rat antrum and colon. J. Clin. Gastroenterol., 20(s2):S8-S13.

[25]Ohara, S., Hongo, M., Asaki, S., Sato, A., Shibuya, D., Sato, H., Motojima, T., Yamaguchi, N., Ohara, T., Tamura, T., et al., 1988. The effects of famotidine and omeprazole on 24-hour intragastric pH of normal subjects. Nippon Shokakibyo Gakkai Zasshi, 85(7):1353-1359 (in Japanese).

[26]Saito, H., Sugiyama, A., Sato, T., 2000. An influence on the human gastric surface mucous gel layer of roxatidine acetate hydrochloride. Ulcer Res., 27(1):132-134 (in Japanese).

[27]Saitoh, T., Fukushima, Y., Otsuka, H., Hirakawa, J., Mori, H., Asano, T., Ishikawa, T., Katsube, T., Ogawa, K., Ohkawa, S., 2002. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment. Pharmacol. Ther., 16(10):1811-1817.

[28]Shirai, N., Furuta, T., Moriyama, Y., Okochi, H., Kobayashi, K., Takashima, M., Xiao, F., Kosuge, K., Nakagawa, K., Hanai, H., et al., 2001. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment. Pharmacol. Ther., 15(12):1929-1937.

[29]Smythe, M.A., Zarowitz, B.J., 1994. Changing perspectives of stress gastritis prophylaxis. Ann. Pharmacother., 28(9):1073-1085.

[30]Stothert, J.C.Jr., Dellinger, E.P., Simonowitz, D.A., Schilling, J.A., 1980. Gastric pH monitoring as a prognostic indicator for the prophylaxis of stress ulceration in the critically III. Am. J. Surg., 140(6):761-763.

[31]Tarutani, M., Sakuma, H., Shiratsuchi, K., Mieda, M., 1985. Histamine H₂-receptor antagonistic action of N-(3-[3-(1-piperidinylmethyl)phenoxy]propyl)acetoxyacetamide hydrochloride (TZU-0460). Arzneimittelforschung, 35(4):703-706.

[32]Watanabe, Y., Tsumura, H., Sasaki, H., Morimoto, T., 1990. The effects of intermittent and continuous intravenous infusion of famotidine on gastric acidity in patients with peptic ulcers. Clin. Ther., 12(6):534-546.

[33]Wedlund, P.J., Aslanian, W.S., McAllister, C.B., Wilkinson, G.R., Branch, R.A., 1984. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin. Pharmacol. Ther., 36(6):773-780.

[34]Williams, M.P., Sercombe, J., Hamilton, M.I., Pounder, R.E., 1998. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment. Pharmacol. Ther., 12(11):1079-1089.